<DOC>
	<DOC>NCT01128335</DOC>
	<brief_summary>This study will assess the safety and efficacy of different doses of sotrastaurin when combined with tacrolimus for the prevention of acute rejection after de novo liver transplantation.</brief_summary>
	<brief_title>Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criteria: Recipients of any race, 18 years or older Recipients of primary de novo orthotopic liver transplant from a deceased donor Recipients of a kidney with a cold ischemia time &lt; 30 hours HCVnegative recipients Exclusion criteria: Prior organ/cellular transplant or multiple organ transplant MELDscore &gt; 35 HCC &gt; Milan criteria Donor age &lt; 12 years Cold ischemia &gt; 15 hours Patients who are treated with drugs that are strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) or drugs with QTprolonging properties Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>HCV-negative recipient</keyword>
	<keyword>deceased donor</keyword>
	<keyword>sotrastaurin</keyword>
	<keyword>oran transplantation</keyword>
	<keyword>tacrolimus</keyword>
</DOC>